#Japan #Tokyo #Rakuten Medical #ASP-1929 #Pembrolizumab

Rakuten Medical's Breakthrough Presentation at ESMO 2026

On October 23, 2026, in Madrid, Spain, Rakuten Medical showcased encouraging long-term follow-up results from the Phase 1b/2 ASP-1929-181 clinical study. This study evaluated the effectiveness of the innovative ASP-1929 photoimmunotherapy combined with pembrolizumab in patients suffering from recurrent and/or metastatic head and neck squamous cell carcinoma (r/m HNSCC) during the European Society for Medical Oncology (ESMO) Congress 2026. The presentation highlighted key findings that offer hope for improved treatment outcomes in this challenging cancer context.

Study Overview and Results

Previously reported findings from the ASP-1929-181 study indicated durable clinical activity and manageable safety profiles after a median of 31.7 months of follow-up. The current presentation extended this follow-up to an impressive median duration of 53.1 months. The study included 19 patients diagnosed with r/m HNSCC; however, the long-term follow-up analysis focused on 17 efficacy-evaluable patients.

Key Findings

1. Median Overall Survival: Participants demonstrated a median overall survival of 28.2 months, providing a solid indicator of treatment efficacy. The estimated overall survival rates were 47.1% at 36 months and 35.3% at 48 months.
2. Durability of Treatment Response: A significant finding was that four out of five patients (approximately 29%) who achieved a complete response remained alive, with follow-up sessions extending from over 42 months to more than 60 months.
3. Duration of Response: Notably, the median duration of response was documented at an impressive 44.3 months, showcasing the sustained effectiveness of the treatment.
4. Safety Profile: Importantly, throughout the extended follow-up, no new safety signals were reported, underscoring the safety of the ASP-1929 combination treatment.

These findings reinforce the potential of ASP-1929 as a treatment option for patients facing the challenges posed by recurrent and/or metastatic head and neck squamous cell carcinoma.

Ongoing Research and Future Directions

Rakuten Medical is currently advancing its research efforts through the global Phase 3 ASP-1929-381 study. This trial investigates the effects of ASP-1929 photoimmunotherapy combined with pembrolizumab as a first-line treatment for locoregional recurrent HNSCC. As the company pushes forward with its research, it is committed to evaluating the insights obtained from the Phase 1b/2 study in light of the trial's limitations, including limited patient numbers and small sample sizes in some analyses.

In anticipation of potential future success, Rakuten Medical aims to submit a Biologics License Application (BLA) for ASP-1929 to the U.S. FDA by the year 2028. The commitment to ongoing research speaks volumes about the potential this innovative therapy holds in the fight against cancer.

About the Alluminox® Platform

ASP-1929 is developed utilizing Rakuten Medical's proprietary Alluminox® platform. This groundbreaking platform merges pharmaceuticals and medical technology to innovate in photoimmunotherapy. The treatment consists of an antibody-dye conjugate that binds specifically to cancer cells, which are then activated through targeted illumination to induce selective cell necrosis. Such targeted approaches may also stimulate local immune responses, offering a dual mechanism against tumor cells.

Conclusion

As Rakuten Medical continues to unveil promising results and invests in further research, the hope for better treatment options for those battling recurrent and metastatic head and neck squamous cell carcinoma grows. The commitment to developing innovative therapies reflects a mission to conquer cancer and improve patient outcomes on a global scale. Rakuten Medical's journey represents a beacon of hope in oncology, and the upcoming clinical trials will be closely watched by the medical community and patients alike.